香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：01456） （於中華人民共和國成立的股份有限公司） 關於子公司重大訴訟的進展公告 近日，國聯民生承銷保薦收到山東省濟南市中級人民法院（「濟南中院」或「本院」）送 達的《民事判決書》，現將相關信息公告如下： 一、訴訟的基本情况 1 原告： 李立群等1,618名投資者（投資者人數已經濟南中院審查確認） 代表人： 李立群、萬雲、孫靜、田慶龍、李明臣 被告： 山東龍力生物科技股份有限公司（「龍力生物」）、程少博等12名 自然人、國聯民生承銷保薦、立信會計師事務所（特殊普通合夥） （「立信會計」） 案由： 證券虛假陳述責任糾紛 訴訟方式： 普通代表人訴訟 二、原告訴訟請求、事實和理由 （一）原告訴訟請求 （二）訴訟事實和理由 原告訴稱，因龍力生物的虛假陳述行為，中國證券監督管理委員會對龍力 生物等主體作出相應處罰。各原告在相關期間買入並持有龍力生物股票的 損失與龍力生物虛假陳述行為之間存在因果關係。 ...

Product Prices and Market Performance - Overall demand has decreased due to the pharmaceutical environment, but the three main intermediate products of the company have shown varied performance. The price of thiocyanate erythromycin has risen slightly, with a single-digit increase since the beginning of the year, and is expected to remain stable in the second half of the year. The price of cephalosporin products is stable and is expected to maintain the current situation in the second half. The price of penicillin has decreased since the beginning of the year, but with increasing industry concentration, it is becoming more difficult for small companies to enter the market. An increase in demand is expected in the fourth quarter, which may improve the situation [1]. Synthetic Biology and Project Progress - Sales of synthetic biology products are steadily advancing, with the company achieving a revenue of 22.32 million yuan in the first half of the year. With adjustments and releases in production capacity, future sales are expected to increase. The methanol protein project has undergone trials in a 30m³ fermentation tank, with initial results available and samples sent to downstream manufacturers for testing. The company is also actively applying for qualifications from the Ministry of Agriculture and Rural Affairs [2]. Overseas Capacity and Domestic Planning - After assessment, the company has decided to postpone its entry into Kazakhstan due to several uncontrollable risks. The first phase of the company is in a rapid development stage, and the second phase will be determined based on the R&D progress of the Shanghai Research Institute and the release of first-phase capacity [3]. Order Expectations and Capital Expenditure - The company anticipates growth in orders with Kelun Yongnian Company for ergotamine. There are no significant capital expenditures expected in the short term, with fixed asset depreciation for the first half of 2025 amounting to 273 million yuan, an increase of 22 million yuan year-on-year. Starting in 2026, the main equipment depreciation is expected to decrease significantly, with a projected reduction of tens of millions if no new fixed assets are added by the end of 2027 [4]. R&D and Product Selection Planning - Future R&D will focus on four main areas: traditional product synthesis and biological modification; technology enhancement and cost reduction for delivered products; efficient biological utilization of C1/C2 resources; and the development of amino acids and vitamin products [5]. Cost Trends and Import-Export Situation - The price of the main raw material, corn, is expected to rise to 1.8 - 1.9 yuan/kg in November. Energy costs, particularly coal prices, have decreased compared to 2024 and are expected to remain stable in the coming years. The export amount has increased by approximately 25% compared to the same period last year, mainly due to increased exports of thiocyanate and 6-APA, while cephalosporin exports have slightly decreased. Exports are primarily directed towards India and Hong Kong, with tariffs having minimal impact on the company's exports [6]. Gross Margin and Production Efficiency - With the increase in synthetic biology product volume and the application of AI technology, the company has room for improvement in gross margin. AI-controlled fermentation tank output exceeds the control group by 3% - 5%, reducing production fluctuations and enhancing R&D efficiency. The overall gross margin for the company in the first half of 2025 was 35.90%, a year-on-year increase of 0.55%, while the gross margin for pharmaceutical intermediates was 38.64%, a year-on-year increase of 1.37% [7]. Expenses and Performance Outlook - The sales expense ratio for the first half of 2025 was 0.58%, an increase of 0.21% year-on-year, and is expected to remain stable in the second half. The management expense ratio was 3.37%, an increase of 0.13% year-on-year, while the financial expense ratio was 0.67%, a decrease of 0.19% year-on-year. The company is facing performance pressure this year due to the impact of penicillin prices, with expectations of a decline compared to last year. However, in 2026, with the increase in synthetic biology product volume and the recovery of penicillin prices, performance and profits are expected to improve [8].

Group 1 - The core point of the news is that Shuangyuan Technology (688623.SH) is currently experiencing a decline in stock price, closing at 68.72 yuan with a drop of 3.40%, resulting in a total market capitalization of 4.064 billion yuan, indicating that the stock is in a state of breaking issue [1] - The stock was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 8, 2023, with an initial offering price of 125.88 yuan per share and a total issuance of 14.7857 million shares [1][2] - On its first trading day, the stock reached a peak price of 120.00 yuan but has since experienced fluctuations leading to a downward trend [2] Group 2 - Shuangyuan Technology raised a total of 1.861224 billion yuan through its initial public offering, with a net amount of 1.6663587 billion yuan after deducting issuance costs, which exceeded the originally planned fundraising amount by 1.0147809 billion yuan [2] - The company intended to use the raised funds for projects including the construction of an intelligent measurement and control equipment production base, a research and development center, a marketing network, and to supplement working capital [2] - The underwriting institution for Shuangyuan Technology is Minsheng Securities Co., Ltd., which received a total underwriting fee of 170.7192 million yuan from the issuance [2][3] Group 3 - The strategic placement of shares involved Minsheng Securities Investment Co., Ltd., which acquired 476,644 shares, accounting for 3.22% of the total issuance, with an investment amount of approximately 60 million yuan [3] - Minsheng Securities Investment Co., Ltd. has committed to holding the allocated shares for a period of 24 months from the date of the initial public offering and listing [3]

证券日报网讯 8月25日晚间，国联民生发布公告称，近日，国联民生证券股份有限公司全资子公司国联 民生证券承销保荐有限公司完成法定代表人变更登记手续，其法定代表人由葛小波变更为徐春，并取得 了上海市市场监督管理局换发的营业执照。 （文章来源：证券日报） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：01456） （於中華人民共和國成立的股份有限公司） 海外監管公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條作出。 如下公告已於上海證券交易所網站刊發，僅供參閱。 特此公告。 承董事會命 國聯民生證券股份有限公司 董事長 顧偉 中國江蘇省無錫市 2025年8月25日 截至本公告日期，本公司執行董事為葛小波先生；本公司非執行董事為顧偉先生、 周衛平先生、吳衛華先生、楊振興先生及劉海林先生；及本公司獨立非執行董事為 高偉先生、郭春明先生及徐慧敏女士。 证券代码：601456 证券简称：国联民生 公告编号：2025-054 号 国联民生证券股份有限公司 关于子公司完成法定代表人工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，国联民生证券股份有限公司全资子公司国联民 ...

关于子公司完成法定代表人工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，国联民生证券股份有限公司全资子公司国联民生证券承销保荐有限公 司完成法定代表人变更登记手续，其法定代表人由葛小波变更为徐春，并取得了 上海市市场监督管理局换发的营业执照，相关登记信息如下： 证券代码：601456 证券简称：国联民生 公告编号：2025-054 号 国联民生证券股份有限公司 统一社会信用代码：91320214717884755C 名称：国联民生证券承销保荐有限公司 类型：有限责任公司（非自然人投资或控股的法人独资） 住所：中国（上海）自由贸易试验区浦明路 8 号 特此公告。 国联民生证券股份有限公司董事会 2025 年 8 月 25 日 1 注册资本：人民币 20,000 万元整 成立日期：2011 年 04 月 20 日 经营范围：许可项目：证券业务；债券市场业务。（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准）一般项目：证券财务顾问服务。（除依法须经批准 ...

Meeting Details - The shareholders' meeting was held on August 22, 2025, at the Guolian Financial Building, Wuxi, Jiangsu Province [1] - A total of 1,240 A-share shareholders and 1 H-share shareholder attended the meeting, with A-share shareholders holding 3,069,923,474 shares (54.04% of total shares) and H-share shareholders holding 57,706,995 shares (1.02% of total shares) [1] - The voting method combined on-site and online voting, complying with relevant laws and regulations [1] Voting Results - Non-cumulative voting proposals were approved with A-share votes showing 99.85% in favor and H-share votes showing 96.09% in favor [1] - The total votes for ordinary shares were 3,120,619,814, with 99.78% in favor [1] Legal Compliance - The meeting was conducted in accordance with the Company Law and the Articles of Association, with the presence of legal representatives ensuring the legality of the proceedings [2]

北京德恒（无锡）律师事务所 关于 国联民生证券股份有限公司 法律意见 无锡市滨湖区太湖新城金融一街 15 号平安财富中心 8 层 电话:0510-85215998 传真:0510-85215778 邮编:214000 北京德恒（无锡）律师事务所 关于国联民生证券股份有限公司 北京德恒（无锡）律师事务所 关于 国联民生证券股份有限公司 法律意见 编号：德恒 26G20250100 号 致：国联民生证券股份有限公司 北京德恒（无锡）律师事务所受国联民生证券股份有限公司（以下简称"国 联民生"或"公司"）委托，指派本所律师出席国联民生证券股份有限公司 2025 年 第二次临时股东大会（以下简称"本次股东大会"），并对本次股东大会的合法性 进行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》 （以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等规定以及本法律意见出具日以前已 经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 北京德恒（无锡）律师事务所 关于国联民生证 ...

国联民生（601456）(01456)发布公告，经股东于临时股东大会上批准，徐慧敏女士已获选举为第五届 董事会独立非执行董事。徐慧敏女士将接替朱贺华先生担任公司独立非执行董事、董事会战略与ESG委 员会及审计委员会委员等职务，任期至第五届董事会任期届满之日止。 自徐慧敏女士任职之日起，朱贺华先生将不再担任公司独立非执行董事、董事会战略与ESG委员会及审 计委员会委员等职务。 ...

证券代码：601456 证券简称：国联民生 公告编号：2025-053 号 国联民生证券股份有限公司 关于独立董事任职的公告 附件： 徐慧敏女士，1970 年生，中国香港居民，香港中文大学工商管理学士，美 国注册会计师协会会员。徐慧敏女士现任完美医疗健康管理有限公司（01830.HK） 独立董事，裕田中国发展有限公司（00313.HK）独立董事，华显光电技术控股 有限公司（00334.HK）独立董事，北京燃气蓝天控股有限公司（06828.HK）独 立董事，圆美光电有限公司（08311.HK）独立董事，曾任香港安永会计师事务 所审计师和审计合伙人，中国森林控股有限公司（00930.HK）独立董事等职务。 徐慧敏女士与公司的董事、监事、高级管理人员、实际控制人及持股 5%以 上的股东不存在关联关系，不存在《上海证券交易所上市公司自律监管指引第 1 号——规范运作》第 3.2.2 条所列情形，未持有公司股票。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2 国联民生证券股份有限公司（以下简称"公司"）于 2025 年 8 月 2 ...